U.S. Firm Set To Sue S. Korea Dog Cloner Tied To Disgraced Scientist
This article was originally published in PharmAsia News
Executive Summary
A U.S. company is reported set to file suit in South Korea, charging a patent violation involving the country's disgraced South Korean cloning scientist. Start Licensing, which holds a license from the U.K.'s Roslin Institute, famous for cloning Dolly the sheep, has hired a South Korean patent lawyer to sue RNL Bio of South Korea, a commercial dog-cloning company. Start says it licensed commercial rights for the Roslin technology to BioArts, which in turn relies on the work of Hwang Woo-suk, infamous South Korean stem cell cloner. A former Hwang collaborator provides cloning technology to RNL, completing the circle of involvement and alleged conflict. (Click here for more
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.